GEHC

AI Research

GE Healthcare FDA Clearances for 3 Next-Gen MRI Products → 2026 Adjusted EPS Guided $4.95-5.15

GE Healthcare received FDA clearances for three next-generation MRI products featuring AI-enhanced imaging capabilities, strengthening its position in the medical imaging equipment market as the company guided 2026 adjusted EPS to $4.95-5.15. Analysts hold a Buy consensus with an average price target of $93.05, reflecting confidence in the company's imaging and patient monitoring portfolio refresh. Risks include hospital capital spending budget pressures, competition from Siemens Healthineers and Philips in medical imaging, and supply chain constraints for advanced imaging components.